Nkarta Therapeutics

Nkarta is a clinical-stage biotechnology company advancing allogeneic, off-the-shelf natural killer (NK) cell therapies to treat autoimmune disease. Combining cell expansion and cryopreservation platforms with proprietary engineering technologies, Nkarta's lead candidate NKX019 uses donor-derived NK cells to target B cell-mediated autoimmune conditions including lupus, enabling outpatient community health setting dosing.